The executive medical lead at Italfarmaco SpA expressed his confidence in givinostat to mitigate the progression of Duchenne muscular dystrophy, emphasizing its multifactorial mechanism of action. [WATCH TIME: 5 minutes]
Marcello Paglione, PhD
Advertisement
Executive medical lead at Italfarmaco SpA.
Articles by Marcello Paglione, PhD
The executive medical lead at Italfarmaco SpA talked about data from both animal models and clinical trials supporting the efficacity of givinostat in patients with Duchenne muscular dystrophy at MDA 2024. [WATCH TIME: 5 minutes]
Advertisement
Latest Updated Articles
Evaluating Givinostat's Efficacy and Safety in Duchenne Muscular Dystrophy: Marcello Paglione, PhDPublished: April 3rd 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Early Results Show Symptom Gains in First Patient Dosed With UX-DA001 Cell Therapy for Parkinson Disease
2
Testing D1 Receptor Modulator Glovadalen in Phase 2 Trial for Parkinson Disease: Milton Biagioni MD, CMD
3
Mechanistic Rationale Behind Amlenetug to Treat Multiple System Atrophy: Johan Luthman, PhD
4
This Week on NeurologyLive® — October 20, 2025
5
